Survodutide Phase II trial shows 83% of adults treated achieved groundbreaking results in liver disease due to MASH, with significant improvements in fibrosis
Globe Newswire26-02-2024, 14:05
Industry leaders to speak at Wood Mackenzie’s Carbon Capture, Utilization and Storage Conference 2024 17-09-2024, 18:00